Smeland S, et al. - Researchers undertook the European and American Osteosarcoma Study (EURAMOS)-1—a collaboration of four study groups—to improve the outcomes of osteosarcoma via facilitating randomized controlled trials. Eligible patients included those aged ≤ 40 years with M0 or M1 skeletal high-grade osteosarcoma and with the possibility for case complete surgical resection at all sites. Survival rates in concordance with institution- or group-level osteosarcoma trials were evident. At a median follow-up of 54 months from biopsy, 3- and 5-year event-free survival rates were 59% and 54%, respectively, for all registered cases. As per multivariate analyses, pulmonary metastases, non-pulmonary metastases, or an axial skeleton tumor site were the most adverse factors observed at diagnosis. A favorable prognosis was noted for the histological subtypes telangiectatic and unspecified conventional compared with chondroblastic subtype.